arrow

From NeuroLex

Jump to: navigation, search



Cladribine

Name: Cladribine
Description: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. (PubChem) Pharmacology: Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites.Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply. Mechanism of action: Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. It is phosphorylated to its corresponding nucleotide CdATP, which accumulates and is incorporated into the DNA of cells such as lymphocytes. High levels of CdATP lead to DNA strand breaks, inhibition of DNA synthesis, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Immunosuppressive Agents
Synonym(s): 2-CdA, 2-Chloro-2'-deoxy-beta-adenosine, 2-Chloro-2'-deoxyadenosine, 2-Chlorodeoxyadenosine, Chlorodeoxyadenosine, cladribine, Leustatin, Mylinax
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB00242
Id: DB00242
Related to: Purine nucleoside phosphorylase, DNA, Adenosine deaminase
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Ccdbuser, Nifbot2



bookmark
Facts about CladribineRDF feed
Commenttaken from DrugBank
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB00242  +
DefinitionAn antineoplastic agent used in the treatm An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. (PubChem) Pharmacology: Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites.Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply. Mechanism of action: Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. It is phosphorylated to its corresponding nucleotide CdATP, which accumulates and is incorporated into the DNA of cells such as lymphocytes. High levels of CdATP lead to DNA strand breaks, inhibition of DNA synthesis, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established. Drug type: Approved. Investigational. Small Molecule. Drug category: Antineoplastic Agents. Immunosuppressive Agents eoplastic Agents. Immunosuppressive Agents
Has roleDrug  +
IdDB00242  +
LabelCladribine  +
ModifiedDate14 April 2014  +
RelatedToPurine nucleoside phosphorylase  +, DNA  +, and Adenosine deaminase  +
SuperCategoryMolecular entity  +
Synonym2-CdA  +, 2-Chloro-2'-deoxy-beta-adenosine  +, 2-Chloro-2'-deoxyadenosine  +, 2-Chlorodeoxyadenosine  +, Chlorodeoxyadenosine  +, cladribine  +, Leustatin  +, and Mylinax  +